Shopping Cart 0
Cart Subtotal
USD 0

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Systemic Sclerosis (Scleroderma)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma)-Pipeline Review, H2 2018, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 15, 9, 1, 31 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).

- The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Systemic Sclerosis (Scleroderma)-Overview 6

Systemic Sclerosis (Scleroderma)-Therapeutics Development 7

Systemic Sclerosis (Scleroderma)-Therapeutics Assessment 19

Systemic Sclerosis (Scleroderma)-Companies Involved in Therapeutics Development 31

Systemic Sclerosis (Scleroderma)-Drug Profiles 50

Systemic Sclerosis (Scleroderma)-Dormant Projects 299

Systemic Sclerosis (Scleroderma)-Discontinued Products 301

Systemic Sclerosis (Scleroderma)-Product Development Milestones 302

Appendix 310


List Of Figure

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2018 15

Number of Products under Development by Companies, H2 2018 16

Number of Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Top 10 Targets, H2 2018 27

Number of Products by Stage and Top 10 Targets, H2 2018 27

Number of Products by Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 31

Number of Products by Routes of Administration, H2 2018 35

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 35

Number of Products by Top 10 Molecule Types, H2 2018 37

Number of Products by Stage and Top 10 Molecule Types, H2 2018 37


List Of Table

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Abide Therapeutics Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by AnaMar AB, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Anima Biotech Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by arGentis Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Bayer AG, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Biogen Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by BriaCell Therapeutics Corp, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Bristol-Myers Squibb Co, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Capella Bioscience Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Covis Pharmaceuticals Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by CSL Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Cumberland Pharmaceuticals Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Fibrocell Science Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Formation Biologics Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Fresenius SE & Co KGaA, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by GenKyoTex SA, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Gilead Sciences Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by GlaxoSmithKline Plc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by GNI Group Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by iBio Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Inventiva, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Kadmon Corp LLC, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Leadiant Biosciences Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Link Genomics Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by MallInckrodt Plc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Nuevolution AB, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Patagonia Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by PDX Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Peptinov SAS, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Pfizer Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by ProMetic Life Sciences Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Resolys Bio Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Ribomic Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Samumed LLC, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Sanofi, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Seattle Genetics Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Stemline Therapeutics Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Unity Biotechnology Inc, H2 2018

Systemic Sclerosis (Scleroderma)-Pipeline by Vicore Pharma AB, H2 2018

Systemic Sclerosis (Scleroderma)-Dormant Projects, H2 2018

Systemic Sclerosis (Scleroderma)-Dormant Projects, H2 2018 (Contd..1), H2 2018

Systemic Sclerosis (Scleroderma)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Systemic Sclerosis (Scleroderma) Therapeutic Products under Development, Key Players in Systemic Sclerosis (Scleroderma) Therapeutics, Systemic Sclerosis (Scleroderma) Pipeline Overview, Systemic Sclerosis (Scleroderma) Pipeline, Systemic Sclerosis (Scleroderma) Pipeline Assessment


Companies

Abide Therapeutics Inc

AnaMar AB

Anima Biotech Ltd

arGentis Pharmaceuticals LLC

Bayer AG

Biogen Inc

Boehringer Ingelheim GmbH

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Capella Bioscience Ltd

Chugai Pharmaceutical Co Ltd

Covis Pharmaceuticals Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fibrocell Science Inc

Formation Biologics Inc

Fresenius SE & Co KGaA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

GNI Group Ltd

iBio Inc

Inventiva

Kadmon Corp LLC

Leadiant Biosciences Inc

Link Genomics Inc

MallInckrodt Plc

Nuevolution AB

Patagonia Pharmaceuticals LLC

PDX Pharmaceuticals LLC

Peptinov SAS

Pfizer Inc

ProMetic Life Sciences Inc

Resolys Bio Inc

Ribomic Inc

Samumed LLC

Sanofi

Seattle Genetics Inc

Stemline Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Unity Biotechnology Inc

Vicore Pharma AB